Cisplatin: Balancing Benefits and Risks Revision Notes | A Level AQA Chemistry

1. Why Cisplatin Matters

A drug that poisons DNA sounds alarming — yet cisplatin has saved hundreds of thousands of lives since its approval in the 1970s. Understanding how it works, and why it causes harm alongside healing, sits at the heart of this topic.

This lesson connects directly to two AQA specification requirements: explaining why anticancer drugs produce adverse effects, and evaluating how society balances those effects against genuine therapeutic benefit. Both demand more than recall — you need to reason from molecular structure to real-world consequence.

2. The Structure of Cisplatin and How It Reaches DNA

Cisplatin has the molecular formula cis-[Pt(NH3)2Cl2]. The word cis is critical: the two chloride ligands sit on the same side of the square-planar platinum centre. The trans isomer, with chloride ligands on opposite sides, is clinically inactive — a neat illustration of how geometry determines biological function.

Once administered intravenously, cisplatin travels through the bloodstream. Inside cells, the relatively low chloride concentration (compared with blood plasma) triggers hydrolysis: one or both chloride ligands are replaced by water molecules, producing positively charged aqua complexes. These aqua complexes are the reactive species that attack DNA.

The guanine base in DNA contains a nitrogen atom (N7) that acts as a nucleophile. The activated platinum complex forms a coordinate bond with N7, and because platinum can bond to two guanine bases simultaneously, it creates an intrastrand cross-link — a physical kink in the DNA double helix that the cell's replication machinery cannot bypass.

3. Why Cisplatin Causes Adverse Effects

Here is the central tension: cisplatin does not distinguish between cancerous cells and healthy cells. Its mechanism — blocking DNA replication by cross-linking guanine bases — affects any cell that is actively dividing. Cancer cells divide rapidly and uncontrollably, which is why they are particularly vulnerable. But the body also contains many populations of healthy, rapidly dividing cells.

• Bone marrow cells: produce red blood cells, white blood cells, and platelets — damage here causes anaemia, increased infection risk, and impaired clotting.
• Hair follicle cells: divide rapidly to produce hair — cisplatin-induced damage causes alopecia (hair loss).
• Cells lining the gastrointestinal tract: rapid turnover means nausea, vomiting, and mucositis are common.
• Kidney tubule cells: cisplatin accumulates in the kidneys and is directly nephrotoxic, potentially causing renal failure.
• Nerve cells: peripheral neuropathy (numbness and tingling) results from damage to sensory neurons.

The root cause of all these adverse effects is the same molecular event: platinum cross-linking DNA in cells that were not the intended target. This is not a flaw in the drug's design so much as a consequence of the fundamental biology — DNA replication is a universal cellular process, not one unique to tumour cells.

A second source of adverse effects is the aqua complex reacting with other nucleophilic molecules in the cell, including proteins containing sulfur-rich cysteine residues. This off-target binding reduces the amount of active drug reaching DNA and contributes to kidney toxicity.

4. Balancing Benefits and Risks: The Societal Dimension

Knowing that cisplatin causes serious adverse effects raises an immediate question: why is it still used? The answer requires moving from molecular chemistry to a broader evaluation of what the drug actually achieves for patients.

Cisplatin is particularly effective against testicular cancer, ovarian cancer, bladder cancer, and certain head-and-neck cancers. For testicular cancer, combination chemotherapy regimens including cisplatin achieve cure rates above 95% — a remarkable outcome for a disease that was once almost universally fatal. The severity of the disease being treated is therefore a crucial factor in any benefit-risk assessment.

Society's assessment of this balance is not static. Regulatory bodies such as the MHRA in the UK and the EMA in Europe require clinical trial data demonstrating that the benefit to a defined patient population outweighs the documented risks before a drug can be licensed. For a life-threatening cancer with no alternative treatment, a higher level of adverse effects may be acceptable. For a less serious condition, the same adverse-effect profile would likely be unacceptable.

Clinicians also individualise the assessment. A patient with pre-existing kidney disease may not be able to tolerate cisplatin's nephrotoxicity; a patient with early-stage, highly cisplatin-sensitive cancer may accept severe short-term side effects for a high probability of cure. The benefit-risk balance is therefore context-dependent, not a single fixed verdict.

5. Resistance and Ongoing Research

One limitation that complicates the benefit side of the assessment is acquired resistance. Some tumour cells develop mechanisms to repair platinum-induced DNA cross-links, pump cisplatin out of the cell, or reduce its uptake. When resistance develops, the drug's efficacy falls while the adverse effects remain — shifting the balance unfavourably.

This has driven research into second- and third-generation platinum drugs such as carboplatin and oxaliplatin, which retain the core platinum-DNA cross-linking mechanism but have modified ligands that alter their toxicity profiles and resistance patterns. Carboplatin, for example, causes less nephrotoxicity and nausea than cisplatin, though it produces greater myelosuppression. The existence of these alternatives illustrates how the benefit-risk balance can be shifted by chemical modification — a direct application of the structure-activity relationship thinking that runs throughout A-level organic chemistry.

6. Exam Technique: Answering Benefit-Risk Questions

Questions on cisplatin at A-level typically use command words such as explain, evaluate, or assess. Each demands a different response structure, and confusing them is one of the most common ways students lose marks.

An explain question requires a cause-and-effect chain. For adverse effects, the chain runs: cisplatin is not selective for cancer cells → it cross-links DNA in any rapidly dividing cell → healthy cells with high division rates are damaged → specific adverse effects follow. Every link in that chain must be explicit; stating the outcome without the mechanism will not earn full marks.

An evaluate question requires you to weigh evidence on both sides and reach a reasoned conclusion. For cisplatin, you must present the benefits (high cure rates for certain cancers, life-threatening disease context, no equivalent alternative) and the adverse effects (nephrotoxicity, myelosuppression, neuropathy, nausea) before concluding whether the balance is favourable — and crucially, stating the conditions under which it is or is not.

Worked example: Constructing a 6-Mark Evaluate Answer on Cisplatin

Evaluate the use of cisplatin as an anticancer drug, considering both its benefits and its adverse effects. [6 marks]

1. Cisplatin forms intrastrand cross-links with guanine bases in DNA, blocking replication in rapidly dividing cancer cells. For testicular cancer, cure rates exceed 95% with cisplatin-based regimens. — [B1] Mechanism stated. [B1] Quantified benefit cited. Examiners reward specific data over vague claims.
2. Because cisplatin cannot distinguish cancer cells from healthy rapidly dividing cells, it also cross-links DNA in bone marrow, gut lining, and hair follicle cells, causing myelosuppression, gastrointestinal damage, and alopecia. — [B1] Mechanism of adverse effects linked back to the same molecular process. This is the key explanatory step — the cause is the same event, not a separate mechanism.
3. Cisplatin also accumulates in kidney tubule cells, reacting with nucleophilic groups in proteins as well as DNA, causing nephrotoxicity that may require dose reduction or discontinuation. — [B1] A second, distinct adverse effect with a mechanistic explanation earns an additional mark.
4. The acceptability of these adverse effects depends on the clinical context. For a life-threatening cancer with no equivalent alternative, severe short-term toxicity may be justified by a high probability of cure. For a less serious condition, the same risk profile would be unacceptable. — [B1] Context-dependence of the benefit-risk balance is a key evaluative point that distinguishes A-grade answers.
5. Overall, for cisplatin-sensitive cancers such as testicular cancer, the benefit-risk balance is strongly favourable given the life-threatening nature of the disease and the high cure rate. For cancers with lower response rates or where safer alternatives exist, the balance is less clear and alternatives such as carboplatin may be preferred. — [B1] A conclusion that is conditional and evidence-based, rather than a blanket 'yes' or 'no', reflects the evaluative demand of the question.

Answer: A full 6-mark response covers: mechanism of action [1], quantified benefit [1], mechanism of adverse effects [1], a second specific adverse effect [1], context-dependence of the balance [1], and a reasoned conditional conclusion [1].

To bring the whole lesson together: the adverse effects of cisplatin are not accidental impurities or manufacturing flaws — they are a direct consequence of the drug's mechanism operating in the wrong cellular context. Society's ongoing use of cisplatin reflects a judgement that, for certain cancers, the magnitude of benefit is sufficient to justify those harms. That judgement is revisited continuously as new drugs, resistance data, and patient outcome evidence accumulate.